Voskuil Jla
Everest Biotech Ltd, Upper Heyford, OX25 5HD, UK.
F1000Res. 2014 Oct 2;3:232. doi: 10.12688/f1000research.4966.2. eCollection 2014.
Despite an impressive growth in the business of research antibodies a general lack of trust in commercial antibodies remains in place. A variety of issues, each one potentially causing an antibody to fail, underpin the frustrations that scientists endure. Lots of money goes to waste in buying and trying one failing antibody after the other without realizing all the pitfalls that come with the product: Antibodies can get inactivated, both the biological material and the assay itself can potentially be flawed, a single antibody featuring in many different catalogues can be deemed as a set of different products, and a bad choice of antibody type, wrong dilutions, and lack of proper validation can all jeopardize the intended experiments. Antibodies endorsed by scientific research papers do not always meet the scientist's requirements either due to flawed specifications, or due to batch-to-batch variations. Antibodies can be found with Quality Control data obtained from previous batches that no longer represent the batch on sale. In addition, one cannot assume that every antibody is fit for every application. The best chance of success is to try an antibody that already was confirmed to perform correctly in the required platform.
尽管研究用抗体业务增长显著，但对商业抗体普遍缺乏信任的情况依然存在。各种问题，每个问题都可能导致抗体失效，这让科学家们感到沮丧。大量资金被浪费在购买和试用一个又一个失败的抗体上，却没有意识到该产品存在的所有陷阱：抗体可能会失活，生物材料和检测方法本身都可能存在缺陷，在许多不同目录中出现的单一抗体可能被视为一组不同的产品，抗体类型选择不当、稀释错误以及缺乏适当验证都可能危及预期的实验。由于规格有缺陷或批次间差异，科研论文认可的抗体也不一定总能满足科学家的要求。可以找到带有以前批次获得的质量控制数据的抗体，但这些数据不再代表在售批次。此外，不能假定每种抗体都适用于每种应用。成功的最佳机会是尝试一种已被证实能在所需平台上正确发挥作用的抗体。
